Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorGeisinger Clinic
About this trial
The purpose of the study is to evaluate prospectively the impact of an electronic health record (EHR) alert on primary care providers' (PCP) referral to Nephrology of Geisinger patients with high risk signs (blood and protein in the urine) of glomerulonephritis. This will help quantify the relative effectiveness of EHR alerts on PCPs' referral patterns.
Eligibility criteria
Qualifiers
Adults aged ≥18 years
Patients receiving care from any Geisinger primary care provider (record of an encounter with a Geisinger PCP within the last 2 years from date of survey implementation)
Patients with high-risk glomerulonephritis features i.e. positive test results for hematuria (urine dipstick result with blood 1+ or greater) and proteinuria (2+ or 3+ protein on dipstick or ACR≥300 mg/g or PCR ≥500 mg/g) collected within 12 months of index date.
Disqualifiers
Patients with a nephrologist appointment in the last 12 months before the index date
Patients with a prior appointment with a nephrologist within the last 2 years before the positive urinalysis test for hematuria (1+ or greater)
Patients with a history of glomerulonephritis and/or kidney failure (dialysis or eGFR < 15 mL/min/1.73m2, or kidney transplantation) at any time during the baseline
Patients receiving palliative care at any time during the baseline
Trial design
Treatments tested in this trial
- Electronic Health Record alert
Treatment groups
1,200 Participants
are divided into 2 treatment groupsSponsors and collaborators
Geisinger Clinic
Lead sponsor
Novartis
Collaborator
Source ClinicalTrials.gov